Compare Manhattan Associates Inc (MANH) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Natera Inc. Common Stock — how do they compare? Manhattan Associates Inc trades at $216.88 (market cap $12.99B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 4.4× Manhattan Associates Inc's market cap, and Manhattan Associates Inc is more actively traded (546,880 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 11 Days and Natera Inc. Common Stock for 0 Days on average.
| MANH | NTRA | |
|---|---|---|
Market Cap | $12.99B | $57.03B |
Volume | 546,880 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $223.76 | $425.64 |
52-Week Low | $120.88 | $179.42 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $12.85B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $222.71, up 2.21% today, with a bullish technical signal and strong profitability metrics including a 96.38% ROE. Recent earnings have consistently beaten expectations, and the company launched new Editions solutions to expand market access. However, high valuation ratios and a legal investigation pose headwinds.
The outlook remains positive with 80% analyst buy ratings and a $219.25 consensus target, but risks include elevated P/E of 63.81 and potential fiduciary breach concerns. Earnings growth and product innovation are key catalysts, yet investors should weigh valuation against legal and competitive pressures.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
